It is clear that patients must always check with physician to confirm confounding asthma and COPD worsening. The variations of bronchitis, exacerbations are delineated amongst the symptomology so common in emphysema and COPD. Excited for this medication.
FDA Approves New COPD Treatment — Physician’s First Watch
FDA Approves New COPD Treatment
By the Editors
The FDA has approved olodaterol (Striverdi Respimat) inhalation spray as a once-daily maintenance therapy for chronic obstructive pulmonary disease.
In a trial of 3100 people with COPD, those who took the medication had improved lung function, compared with those who took placebo. Like other long-acting beta-adrenergic agonists, olodaterol will include a boxed warning highlighting the increase risk for asthma-related death.